Aravive Inc

ARAV NASDAQ
5.93
+0.08
+1.37%
Closed 16:00 06/18 EDT
Open
5.80
Prev Close
5.85
High
5.97
Low
5.80
Volume
8.79K
Avg Vol (3M)
18.11K
52 Week High
15.30
52 Week Low
3.070
% Turnover
0.08%
Market Cap
66.87M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Aravive Inc ARAV stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Aravive, Inc., formerly Versartis, Inc., is a clinical-stage biotechnology company. The Company is focused on developing therapies that target survival pathways for both solid tumors, as well as hematologic malignancies. Its primary therapeutic focus is the growth arrest-specific 6 (GAS6) - AXL receptor tyrosine kinase (AXL) pathway, where AXL receptor signaling promotes metastasis, cancer cell survival, resistance to treatments and immune suppression. The Company’s lead candidate, Aravive-S6 (AVB-S6)-500, is a GAS6 binding protein and AXL decoy receptor. It is a Fc -chimeric fusion protein designed to block the activation of the Growth arrest-specific 6 (GAS6)-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL. Its AXL decoy receptor is a protein based on the extracellular portion of AXL that binds its ligand GAS6, sequesters it from the native receptor and prevents AXLmediated signaling.
MORE >

Recently

Name
Price
%Change